Summary Biopsies from 26 patients with advanced stage squamous cell carcinoma of the head and neck were investigated to determine the intensity of the inflammatory cellular infiltrate and the expression of leucocyte antigens. Mononuclear Tumour growth is influenced by cells and/or products of the tumour's microenvironment. These influences are mainly due to cells of the defence system (Boheim et al., 1987; Kopper & Lapis, 1985; Zeromski et al., 1986; Kabawat et al., 1983) . In vitro assays have demonstrated a significant role for T cells, natural killer (NK) and lymphokine-activated killer (LAK) cells in killing and lysing of neoplastic cells (Patek & Collins, 1988; Strohme et al., 1987; Whiteside et al., 1988; Vinzenz & Micksche, 1987; Gottlinger et al., 1985) . Activated macrophages (Me), also, can bind to and destroy neoplastic cells in vitro and in vivo (Fidler & Schroit, 1984; Fidler & Schroit, 1988; Kopper & Lapis, 1985) . Furthermore, MO, via cytokines, are capable of enhancing lymphocyte-mediated immunity (Bentzen, 1988) . On the other hand, depending on their localisation in tissue, MO may enhance rather than inhibit tumour growth, possible by triggering local immunosuppression (Gronberg et al., 1989; Kopper & Lapis, 1985; Yamanaka et al., 1988; Kronke, 1988) . Considering this bimodal role of MS in immunesurveillance of tumours in vitro we focused our studies on the phenotype and surface receptor expression of MO, which could be involved in local immunesurveillance of malignant growths.
Tumour growth is influenced by cells and/or products of the tumour's microenvironment. These influences are mainly due to cells of the defence system (Boheim et al., 1987; Kopper & Lapis, 1985; Zeromski et al., 1986; Kabawat et al., 1983) . In vitro assays have demonstrated a significant role for T cells, natural killer (NK) and lymphokine-activated killer (LAK) cells in killing and lysing of neoplastic cells (Patek & Collins, 1988; Strohme et al., 1987; Whiteside et al., 1988; Vinzenz & Micksche, 1987; Gottlinger et al., 1985) . Activated macrophages (Me), also, can bind to and destroy neoplastic cells in vitro and in vivo (Fidler & Schroit, 1984; Fidler & Schroit, 1988; Kopper & Lapis, 1985) . Furthermore, MO, via cytokines, are capable of enhancing lymphocyte-mediated immunity (Bentzen, 1988) . On the other hand, depending on their localisation in tissue, MO may enhance rather than inhibit tumour growth, possible by triggering local immunosuppression (Gronberg et al., 1989; Kopper & Lapis, 1985; Yamanaka et al., 1988; Kronke, 1988) . Considering this bimodal role of MS in immunesurveillance of tumours in vitro we focused our studies on the phenotype and surface receptor expression of MO, which could be involved in local immunesurveillance of malignant growths.
Patients and methods

Patients
The study group consisted of 28 patients with histologically confirmed diagnosis of a squamous cell carcinoma of the upper gastro-intestinal and respiratory tract with varying degree of differentiation (Table I (Ledbetter et al., 1981) BD (Wood et al., 1983) BD BD (Leukocyte typing II) (Gooi et al., 1983) BD (Lampson & Levy, 1980) BD (Chen et al., 1984) BD (Chen et al., 1984 ) (Knapp et al., 1984) Dako (Gerdes et al., 1982) Medarex (Graziano & Fanger, 1987) Medarex (Looney et al., 1986) Behring (Simmons & Seed, 1988) BD (Wood et al., 1983 (Zwadlo et al., 1986 Ortho (Zwadlo et al., 1985 ) Leu4 (a-CD3) or VEP9 (a-CD15) were used as described before and staining procedure continued with the respective second moab (Leu3a=a-CD4 or BW209=a-CD16) using an alkaline phosphatase/anti-alkaline phosphatase technique (Cordell et al., 1984) . Controls consisted of irrelevant antibodies of the IgGI (BIP-1) and IgM (SQ4F3) isotypes respectively. Both control moabs reacted with Bet v I, the major allergen from birch pollen (Jarolim et al., 1989 
Results
Clinical histopathology
The tumours were graded histologically into 15 cases of highly, five cases of moderately and eight cases of poorly differentiated squamous cell carcinomas. Mononuclear cell infiltration of the tumours was found to vary considerably between the individual patients and also within each tumour.
T cells, defined by a-CD3, a-CD4 and a-CD8 moabs and MO, stained by MOb-markers (Table II) (Figure 2f ,g,h), CD4 (Figure 2c ), HLA-DR (Figure 4a ), HLA-DP and the Rm3/1 (Figure 2e ) antigens respectively, was found on most MO present in the specimen studied (500-1400 cellsmm-2). Antibodies of this cluster also correlated significantly with each other (Table III) . (Figure 3) . Out of these moabs, only a-CD1lb correlated significantly with the cluster of moabs mentioned above (Table III) . The other moabs (a-CD 1, a-CD35, a-CD36, a-HLA-DQ, 25F9, 27E10) formed a different group showing strong correlation between CD36 and CD35 (r = 0.772 P<0.001). Moabs 27E10 and a-CD36 particularly stained perivascular cells with monocyte morphology (Figure  3b,d ). Anti-CD1, which recognises an epitope on Langerhans cells of the skin, in most cases stained only few cells in tumour specimens, which -unlike T cells or other MOwere found mainly within solid tumour nests (Figure 3a) . In six patients, only small numbers (58-155 mm-2) of CD3+ lymphocytes were present in the tumour tissue, and in these cases also the number of MO was low (169-502 mm-2). The differences in the MO-marker expression between these six and the other 22 patients were significant with respect to moabs a-CD4, a-Fc'y receptors I, II, III, a-HLA-DR and Rm3/1. Only minor or no significant differences were seen with the other Mo/Mb moabs 27E10, a-CD1, 25F9, a-CD36, a-CD35, a-HLA-DQ and a-CD1lb (Figure 1 ). 
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Independently from the histological grading of the whole tumour, in 11 cases the tumour cells expressed class II antigens (Figure 4a ). In 13 specimens, tumour cells forming more differentiated parts -like horny pearls or stratified epithelium -reacted with moab 27E10 and a-CD36 (Figure  4b,c) .
Low numbers of B cells (CD22+ cells) and granulocytes (CD15+ cells) were detected in the tissues studied, the latter cells being found predominantly in necrotic areas (data not shown).
Discussion
The highly divergent results on the numbers of tumour infiltrating Mo/Mb may be due to the fact that these cells mainly express functional antigens, present on the surface of these cells only during certain steps of activation. Characterisation of cultured blood Mo showed that at the beginning of culture about 60% express the 27E10-antigen (Zwadlo et al., 1986) and will loose it in favour of the antigens Rm3/1 and later 25F9 (Zwadlo et al., 1985; . Other studies pointed out that cultured blood Mo gained or showed enhanced expression of Fcy-receptors (Baumgartner et al., 1988; Clarkson & Ory, 1988) , HLA-DR (Peters et al., 1987) or the CD4 antigen (Crowe et al., 1987) . The results of our study indicate that most MS found in tumour tissues are of a functionally 'mature' phenotype. It is not surprising that in our study the number of MO expressing these antigens correlated with a high number of infiltrating T cells, as T lymphocyte products may account for migration of mononuclear phagocytes and further enhance their differentiation towards mature effector cells (Burchett et al., 1988; Makovsky et al., 1988) .
It is certainly of interest to compare the tumour infiltrate seen in squamous cell carcinomas with the infiltrate found in tumours and inflammatory tissues of other origin. Other authors found that in malignant melanomas and gastric carcinomas 27E1O0 and 25F9+ macrophages were associated with tumour progression (Brocker et al., 1987; Heidl et al., 1987; Brocker et al., 1988) . In acute gingival inflammation the dominant Mo/MO population carried the 27E10 antigen, whereas the numbers of Rm3/1 and 25F9 positive cells were low (Zwadlo et al., 1985 (Zwadlo et al., , 1986 . Furthermore, double staining revealed that all three markers labelled distinct, non overlapping MO subpopulations. In contrast, in chronic inflammatory processes high numbers of Rm3/1 and 25F9 positive cells were found, some of these cells carrying both antigens simultaneously . Our present results with the tumour tissue thus resembles the pattern of Mo/Mb infiltration found in chronic inflammatory lesions.
In spite of the marked inflammatory reaction within the tumours of most patients, we could not correlate the number of T lymphocytes with histological grading or tumour differentiation. This finding makes a major influence of tumour malignancy on the number and composition of inflammatory infiltrates unlikely, although subtle differences may have escaped detection because of the limited number of patients and tumour samples investigated. Furthermore, functional defects of immunocompetent cells or the lack of specific immunological responses against putative tumour antigens may explain the ineffectivity of the infiltration to destroy the tumour tissue.
Thus, functional properties of tumour infiltrating cells have to be characterised in vitro and in situ in more detail, by excluding a crucial defect in cytokine and cytotoxin production. This appears to be especially important, since trials are already performed using immune response modifiers or specific anti-tumour antibodies in the treatment of malignancies (Ozawa et al., 1989; Mace et al., 1988) . The finding that squamous cell carcinoma cells may express MO markers (as MHC class II antigens, 27E10, CD36 in this study) was also described by Russel et al. (1988) , who found the expression of PGP-1, which is strongly expressed by mouse phagocytes, also on human bladder carcinoma cells when these cells were transplanted into nude mice. These data suggest that these MO antigens could be induced by mediators of the defence system to generate additional molecules for intercellular adhesion. It seems further likely that squamous carcinoma cells only with a certain differention-grade would be able to express these antigens.
In our study, it is shown that the tumour-infiltrating Mo/ MO population is equipped with surface antigens necessary for enhanced cellular interaction and tumour cell killing. These MO could eventually act as specific effector cells, e.g. when a monoclonal antibody is added -which in turn gives them an important role in future immunotherapy.
